Search Results

You are looking at 1 - 10 of 899 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma

Marina Deuker, Giuseppe Rosiello, Lara Franziska Stolzenbach, Thomas Martin, Claudia Collà Ruvolo, Luigi Nocera, Zhe Tian, Frederik C. Roos, Andreas Becker, Luis A. Kluth, Derya Tilki, Shahrokh F. Shariat, Fred Saad, Felix K.H. Chun, and Pierre I. Karakiewicz

tumor might still lead to survival benefits for highly selected patients with metastases. The importance of stratification according to age and sex has been suggested in other studies, 4 , 5 but it has never been applied to a sufficiently large sample

Full access

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen

Background More than one-third of patients with metastatic non–small cell lung cancer (mNSCLC) will develop bone metastases during the course of their illness. 1 Development of bone metastases often leads to significant morbidity, with

Full access

Clinical Discussion and Review of the Management of Brain Metastases

Priscilla K. Brastianos, William T. Curry, and Kevin S. Oh

Background An estimated 8% to 10% of patients with cancer will develop symptomatic brain metastases. 1 , 2 The geographic distribution of metastases reflects the volume of brain parenchyma and vascular flow: approximately 80% within cerebral

Full access

Local Therapies for Hepatic Metastases

Fabian M. Johnston, Michael N. Mavros, Joseph M. Herman, and Timothy M. Pawlik

Traditionally, local therapy for hepatic metastases has been largely reserved for patients with colorectal liver metastases (CRLM) or, less often, neuroendocrine liver metastases (NELM). Colorectal cancer is one of the most common types of cancer

Full access

Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

adjuvant setting of breast cancer might have any effect on the natural course of the disease. Most specifically, they investigated for any beneficial effects on overall survival, prevention of disease recurrences, and occurrence of bone metastases

Full access

A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer

Kazuki Sudo, Xuemei Wang, Lianchun Xiao, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, David C. Rice, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Adarsh Hiremath, Nikolaos Charalampakis, Ritsuko Komaki, Mariela A. Blum, Stephen G. Swisher, Dipen M. Maru, Heath D. Skinner, Jeana L. Garris, Jane E. Rogers, Wayne L. Hofstetter, and Jaffer A. Ajani

Background Among patients with localized esophageal cancer (LEC), 35% or more develop distant metastases (DM) as first relapse, most in the first 24 months after local therapy. 1 Worldwide, yearly new cases of esophageal cancer are estimated

Full access

The Role of Bisphosphonates in Breast Cancer

Richard L. Theriault

OS Munro AJ Tannock IF . Bone metastases: pathophysiology and management policy . J Clin Oncol 1991 ; 9 : 509 – 524 . 7 Coleman RE Smith P Rubens RD . Clinical course and prognostic factors following bone recurrence from breast cancer

Full access

Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

Background Brain metastases are a critical site of disease progression in patients with metastatic renal cell carcinoma (mRCC). Large institutional and population-based studies estimate the incidence of brain metastasis to be 5% to 20%, 1

Full access

In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer

Nancy Kemeny

arterial infusion (HAI) for the treatment of liver only metastases. I believe 3 circumstances exist in which HAI therapy may be considered. The first is after liver resection. Four randomized controlled trials address the use of HAI therapy after hepatic

Full access

A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

Background Approximately 15% of patients with colorectal cancer (CRC) have synchronous colorectal liver metastases (CLM; detected at initial diagnosis or during treatment after initial diagnosis), and approximately 30% of patients with CRC have